Park Ha Biological Technology（BYAH）株式概要投資持株会社であるPark Ha Biological Technology Co., Ltd.は、中華人民共和国でスキンケア製品を開発している。 詳細BYAH ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析過去5年間で収益は年間83.5%減少しました。 意味のある時価総額がありません ( $2M )過去1年間で株主の希薄化は大幅に進んだ 意味のある収益がありません ( $3M )+1 さらなるリスクすべてのリスクチェックを見るBYAH Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$1.08350.0% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-24m3m2016201920222025202620282031Revenue US$2.5mEarnings US$109.6kAdvancedSet Fair ValueView all narrativesPark Ha Biological Technology Co., Ltd. 競合他社GMEX RoboticsSymbol: NasdaqCM:GMEXMarket cap: US$1.7mBoqii HoldingSymbol: NYSEAM:BQMarket cap: US$2.6mJowell GlobalSymbol: NasdaqCM:JWELMarket cap: US$5.1mTokyo LifestyleSymbol: NasdaqCM:TKLFMarket cap: US$8.3m価格と性能株価の高値、安値、推移の概要Park Ha Biological Technology過去の株価現在の株価US$1.0852週高値US$2,074.5052週安値US$0.93ベータ01ヶ月の変化1.89%3ヶ月変化-39.15%1年変化-99.85%3年間の変化n/a5年間の変化n/aIPOからの変化-99.47%最新ニュースReported Earnings • Mar 04Full year 2025 earnings released: US$41.38 loss per share (vs US$0.96 profit in FY 2024)Full year 2025 results: US$41.38 loss per share (down from US$0.96 profit in FY 2024). Revenue: US$2.52m (up 6.0% from FY 2024). Net loss: US$24.4m (down US$24.8m from profit in FY 2024).New Risk • Feb 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 111% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 89% per year over the past 5 years. Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Market cap is less than US$10m (US$4.91m market cap). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (US$2.8m revenue).お知らせ • Jan 29Park Ha Biological Technology Co., Ltd. has completed a Composite Units Offering in the amount of $2.45 million.Park Ha Biological Technology Co., Ltd. has completed a Composite Units Offering in the amount of $2.45 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 21,875,000 Price\Range: $0.112 Discount Per Security: $0.008New Risk • Jan 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 89% per year over the past 5 years. Market cap is less than US$10m (US$4.95m market cap). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Revenue is less than US$5m (US$2.8m revenue).お知らせ • Sep 20Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering.Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 11,428,571 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 11,428,571お知らせ • Sep 19Park Ha Biological Technology Co., Ltd., Annual General Meeting, Oct 03, 2025Park Ha Biological Technology Co., Ltd., Annual General Meeting, Oct 03, 2025, at 10:00 China Standard Time. Location: 901, building c phase 2, wuxi international life science innovation campus, 196 jinghui east road xinwu district, wuxi China最新情報をもっと見るRecent updatesReported Earnings • Mar 04Full year 2025 earnings released: US$41.38 loss per share (vs US$0.96 profit in FY 2024)Full year 2025 results: US$41.38 loss per share (down from US$0.96 profit in FY 2024). Revenue: US$2.52m (up 6.0% from FY 2024). Net loss: US$24.4m (down US$24.8m from profit in FY 2024).New Risk • Feb 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 111% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 89% per year over the past 5 years. Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Market cap is less than US$10m (US$4.91m market cap). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (US$2.8m revenue).お知らせ • Jan 29Park Ha Biological Technology Co., Ltd. has completed a Composite Units Offering in the amount of $2.45 million.Park Ha Biological Technology Co., Ltd. has completed a Composite Units Offering in the amount of $2.45 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 21,875,000 Price\Range: $0.112 Discount Per Security: $0.008New Risk • Jan 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 89% per year over the past 5 years. Market cap is less than US$10m (US$4.95m market cap). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Revenue is less than US$5m (US$2.8m revenue).お知らせ • Sep 20Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering.Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 11,428,571 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 11,428,571お知らせ • Sep 19Park Ha Biological Technology Co., Ltd., Annual General Meeting, Oct 03, 2025Park Ha Biological Technology Co., Ltd., Annual General Meeting, Oct 03, 2025, at 10:00 China Standard Time. Location: 901, building c phase 2, wuxi international life science innovation campus, 196 jinghui east road xinwu district, wuxi ChinaReported Earnings • Aug 27First half 2025 earnings released: US$0.74 loss per share (vs US$0.002 profit in 1H 2024)First half 2025 results: US$0.74 loss per share (down from US$0.002 profit in 1H 2024). Revenue: US$1.24m (up 45% from 1H 2024). Net loss: US$19.8m (down US$19.9m from profit in 1H 2024).分析記事 • Jul 10Some Park Ha Biological Technology Co., Ltd. (NASDAQ:PHH) Shareholders Look For Exit As Shares Take 94% PoundingPark Ha Biological Technology Co., Ltd. ( NASDAQ:PHH ) shareholders that were waiting for something to happen have been...New Risk • Jul 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$78.9m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Revenue has declined by 3.1% over the past year. Minor Risks Profit margins are more than 30% lower than last year (20% net profit margin). Revenue is less than US$5m (US$2.4m revenue). Market cap is less than US$100m (US$78.9m market cap).Reported Earnings • Feb 25Full year 2024 earnings released: EPS: US$0.019 (vs US$0.034 in FY 2023)Full year 2024 results: EPS: US$0.019 (down from US$0.034 in FY 2023). Revenue: US$2.38m (down 3.1% from FY 2023). Net income: US$478.6k (down 44% from FY 2023). Profit margin: 20% (down from 35% in FY 2023). The decrease in margin was primarily driven by higher expenses.New Risk • Jan 12New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid.お知らせ • Jan 08Park Ha Biological Technology Co., Ltd. Announces Appointment of Da Yang as an Independent DirectorOn January 7, 2025, the Board approved the appointment of Da Yang (Mr. Yang) as an independent director of the Park Ha Biological Technology Co., Ltd., effective January 7, 2025. Mr. Yang does not have a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K. The biography for Mr. Yang is set forth below: Mr. Yang, aged 37, is an independent director of the Company. Mr. Yang has had many years of experience in sales and marketing. Mr. Yang served as the market director in Beijing New Space Technology Co., Ltd. since January 2021. From June 2017 to June 2020, Mr. Yang was a senior marketing manager in Gome Insurance Brokers Limited. From October 2015 to August 2016, Mr. Yang was an assistant to the general manager in Dade Liangju Trading (Beijing) Co., Ltd. Mr. Yang obtained his college degree in music performance (music) from Capital Normal University in 2008. The Board has determined that Mr. Yang qualifies as an independent director under the rules of the Nasdaq Stock Market LLC. In connection with his appointment, Mr. Yang will be entitled to receive the Company’s standard compensation provided to independent directors, pursuant to the independent director agreement between Mr. Yang and the Company.お知らせ • Dec 27Park Ha Biological Technology Co., Ltd. has completed an IPO in the amount of $4.8 million.Park Ha Biological Technology Co., Ltd. has completed an IPO in the amount of $4.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,200,000 Price\Range: $4 Discount Per Security: $0.28株主還元BYAHUS Specialty RetailUS 市場7D-0.9%5.4%1.2%1Y-99.9%2.6%28.7%株主還元を見る業界別リターン: BYAH過去 1 年間で2.6 % の収益を上げたUS Specialty Retail業界を下回りました。リターン対市場: BYAHは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is BYAH's price volatile compared to industry and market?BYAH volatilityBYAH Average Weekly Movement11.6%Specialty Retail Industry Average Movement7.3%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: BYAHの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: BYAHの 週次ボラティリティ は過去 1 年間で22%から12%に減少しましたが、依然としてUS株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201641Xiaoqiu Zhangparkha.cn投資持株会社であるPark Ha Biological Technology Co., Ltd.は、中華人民共和国でスキンケア製品を開発している。製品販売とフランチャイズ・サービスの2つの分野で事業を展開している。同社は「Park Ha」ブランドで、基礎的な皮膚の物理的保護、角質除去、皮脂膜の修復から表面の微小生態学的バランス、アンチエイジングなど様々な製品を提供している。直営小売店やフランチャイズ店を通じて顧客に製品を販売している。同社は2016年に設立され、中華人民共和国の無錫市に本社を置いている。Park Ha Biological Technology Co., Ltd.はXiaoqiu Holding Ltd.の子会社として運営されている。もっと見るPark Ha Biological Technology Co., Ltd. 基礎のまとめPark Ha Biological Technology の収益と売上を時価総額と比較するとどうか。BYAH 基礎統計学時価総額US$2.26m収益（TTM）-US$24.36m売上高(TTM)US$2.52m0.9xP/Sレシオ-0.1xPER（株価収益率BYAH は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BYAH 損益計算書（TTM）収益US$2.52m売上原価US$142.53k売上総利益US$2.38mその他の費用US$26.75m収益-US$24.36m直近の収益報告Oct 31, 2025次回決算日該当なし一株当たり利益（EPS）-11.63グロス・マージン94.36%純利益率-965.00%有利子負債／自己資本比率0%BYAH の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 14:27終値2026/05/22 00:00収益2025/10/31年間収益2025/10/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Park Ha Biological Technology Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Mar 04Full year 2025 earnings released: US$41.38 loss per share (vs US$0.96 profit in FY 2024)Full year 2025 results: US$41.38 loss per share (down from US$0.96 profit in FY 2024). Revenue: US$2.52m (up 6.0% from FY 2024). Net loss: US$24.4m (down US$24.8m from profit in FY 2024).
New Risk • Feb 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 111% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 89% per year over the past 5 years. Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Market cap is less than US$10m (US$4.91m market cap). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (US$2.8m revenue).
お知らせ • Jan 29Park Ha Biological Technology Co., Ltd. has completed a Composite Units Offering in the amount of $2.45 million.Park Ha Biological Technology Co., Ltd. has completed a Composite Units Offering in the amount of $2.45 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 21,875,000 Price\Range: $0.112 Discount Per Security: $0.008
New Risk • Jan 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 89% per year over the past 5 years. Market cap is less than US$10m (US$4.95m market cap). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Revenue is less than US$5m (US$2.8m revenue).
お知らせ • Sep 20Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering.Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 11,428,571 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 11,428,571
お知らせ • Sep 19Park Ha Biological Technology Co., Ltd., Annual General Meeting, Oct 03, 2025Park Ha Biological Technology Co., Ltd., Annual General Meeting, Oct 03, 2025, at 10:00 China Standard Time. Location: 901, building c phase 2, wuxi international life science innovation campus, 196 jinghui east road xinwu district, wuxi China
Reported Earnings • Mar 04Full year 2025 earnings released: US$41.38 loss per share (vs US$0.96 profit in FY 2024)Full year 2025 results: US$41.38 loss per share (down from US$0.96 profit in FY 2024). Revenue: US$2.52m (up 6.0% from FY 2024). Net loss: US$24.4m (down US$24.8m from profit in FY 2024).
New Risk • Feb 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 111% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 89% per year over the past 5 years. Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Market cap is less than US$10m (US$4.91m market cap). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (US$2.8m revenue).
お知らせ • Jan 29Park Ha Biological Technology Co., Ltd. has completed a Composite Units Offering in the amount of $2.45 million.Park Ha Biological Technology Co., Ltd. has completed a Composite Units Offering in the amount of $2.45 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 21,875,000 Price\Range: $0.112 Discount Per Security: $0.008
New Risk • Jan 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 89% per year over the past 5 years. Market cap is less than US$10m (US$4.95m market cap). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Revenue is less than US$5m (US$2.8m revenue).
お知らせ • Sep 20Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering.Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 11,428,571 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 11,428,571
お知らせ • Sep 19Park Ha Biological Technology Co., Ltd., Annual General Meeting, Oct 03, 2025Park Ha Biological Technology Co., Ltd., Annual General Meeting, Oct 03, 2025, at 10:00 China Standard Time. Location: 901, building c phase 2, wuxi international life science innovation campus, 196 jinghui east road xinwu district, wuxi China
Reported Earnings • Aug 27First half 2025 earnings released: US$0.74 loss per share (vs US$0.002 profit in 1H 2024)First half 2025 results: US$0.74 loss per share (down from US$0.002 profit in 1H 2024). Revenue: US$1.24m (up 45% from 1H 2024). Net loss: US$19.8m (down US$19.9m from profit in 1H 2024).
分析記事 • Jul 10Some Park Ha Biological Technology Co., Ltd. (NASDAQ:PHH) Shareholders Look For Exit As Shares Take 94% PoundingPark Ha Biological Technology Co., Ltd. ( NASDAQ:PHH ) shareholders that were waiting for something to happen have been...
New Risk • Jul 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$78.9m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Revenue has declined by 3.1% over the past year. Minor Risks Profit margins are more than 30% lower than last year (20% net profit margin). Revenue is less than US$5m (US$2.4m revenue). Market cap is less than US$100m (US$78.9m market cap).
Reported Earnings • Feb 25Full year 2024 earnings released: EPS: US$0.019 (vs US$0.034 in FY 2023)Full year 2024 results: EPS: US$0.019 (down from US$0.034 in FY 2023). Revenue: US$2.38m (down 3.1% from FY 2023). Net income: US$478.6k (down 44% from FY 2023). Profit margin: 20% (down from 35% in FY 2023). The decrease in margin was primarily driven by higher expenses.
New Risk • Jan 12New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid.
お知らせ • Jan 08Park Ha Biological Technology Co., Ltd. Announces Appointment of Da Yang as an Independent DirectorOn January 7, 2025, the Board approved the appointment of Da Yang (Mr. Yang) as an independent director of the Park Ha Biological Technology Co., Ltd., effective January 7, 2025. Mr. Yang does not have a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K. The biography for Mr. Yang is set forth below: Mr. Yang, aged 37, is an independent director of the Company. Mr. Yang has had many years of experience in sales and marketing. Mr. Yang served as the market director in Beijing New Space Technology Co., Ltd. since January 2021. From June 2017 to June 2020, Mr. Yang was a senior marketing manager in Gome Insurance Brokers Limited. From October 2015 to August 2016, Mr. Yang was an assistant to the general manager in Dade Liangju Trading (Beijing) Co., Ltd. Mr. Yang obtained his college degree in music performance (music) from Capital Normal University in 2008. The Board has determined that Mr. Yang qualifies as an independent director under the rules of the Nasdaq Stock Market LLC. In connection with his appointment, Mr. Yang will be entitled to receive the Company’s standard compensation provided to independent directors, pursuant to the independent director agreement between Mr. Yang and the Company.
お知らせ • Dec 27Park Ha Biological Technology Co., Ltd. has completed an IPO in the amount of $4.8 million.Park Ha Biological Technology Co., Ltd. has completed an IPO in the amount of $4.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,200,000 Price\Range: $4 Discount Per Security: $0.28
